Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Retained Earnings (2016 - 2025)

UroGen Pharma's Retained Earnings history spans 10 years, with the latest figure at -$959.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 19.04% year-over-year to -$959.7 million; the TTM value through Dec 2025 reached -$959.7 million, down 19.04%, while the annual FY2025 figure was -$959.7 million, 19.04% down from the prior year.
  • Retained Earnings reached -$959.7 million in Q4 2025 per URGN's latest filing, down from $23000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $23000.0 in Q3 2025 to a low of -$959.7 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$562.4 million, with a median of -$619.4 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: crashed 13705100.0% in 2022, then soared 100.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$25000.0 in 2021, then crashed by 2308300.0% to -$577.1 million in 2022, then decreased by 17.71% to -$679.3 million in 2023, then fell by 18.68% to -$806.2 million in 2024, then decreased by 19.04% to -$959.7 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Retained Earnings are -$959.7 million (Q4 2025), $23000.0 (Q3 2025), and -$900.0 million (Q2 2025).